Skip to main content
Equibles
ABCL logo

ABCL · AbCellera Biologics Inc.

Track ABCL — free

Use ABCL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ABCL

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.39 +0.15 (+1.18%)
Market Cap
$3.75B
Shares
306.61M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.24 Open$12.22 Day$12.05–12.36 52W close$2.78–12.50 Avg vol 30d8.7M Short int41.3M · 13.5% float · 3.0d Short vol48% Last earningsAug 5, 2026 DataDec 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 2, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 15.2 · calm Equity put/call 0.64
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +152%
      above
      Price vs 50-day avg +61%
      above
      RSI (14) 71
      overbought
      MACD trend Positive
      52-week position 97%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +127%
      trailing
      6-month return +241%
      trailing
      YTD return +258%
      this year
      Relative strength +229%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $8 › 200d $5 — 50d above 200d
      Institutional flow Accumulating
      +8% holders QoQ · +39 funds added
      Insider flow Accumulating
      Net +$1.5M over 90 days · 0% sells
      Short interest Falling
      13.48% of float · ▼ -14.4% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      150 holders — mid 3-yr range
      Squeeze score 68
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +161%
      Y/Y
      EPS growth +11%
      Y/Y
      Free cash flow $-174.1M
      Balance sheet $128.3M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 87%
      annualized · 1-yr
      Max drawdown −55%
      past year
      ATR 7.0%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +152% Bullish
      Price vs 50-day avg
      +61% Bullish
      RSI (14)
      71 Bearish
      MACD trend
      Positive Bullish
      52-week position
      97% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $8 › 200d $5 — 50d above 200d
      Institutional flow Accumulating
      +8% holders QoQ · +39 funds added
      Insider flow Accumulating
      Net +$1.5M over 90 days · 0% sells
      Short interest Falling
      13.48% of float · ▼ -14.4% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      150 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $3 Now $12 · 97% Range high $13
      vs 200-day avg +152% vs 50-day avg +61%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Available non-dilutive government funding $110M Q2 2026 —
      In discovery or preclinical development 35 Q1 2026 —
      In the clinic 5 Q1 2026 —
      Molecules in the clinic with downstreams 14 Q1 2026 —
      Molecules in the clinic 19 FY 2025 —
      Partner-initiated program starts with downstreams 104 FY 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ABCL
      AbCellera Biologics Inc.
      this stock
      		$3.75B +257.9% +160.6% — 13.5%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.72B +20.7% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $83.89B +5.6% +20.8% 20.2 2.3%
      ARGX
      Argenx SE
      		 $65.12B +24.5% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.92B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      150
      % held
      40.0%
      Net QoQ
      -6.9M sh
      Top holder
      BAKER BROS. ADVISORS LP
      Held Float
      View
      Held by Funds
      Fund positions
      23
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      41.3M
      Days to cover
      3.0d
      Change
      -7.0M sh
      View
      Short Volume
      Short vol %
      48%
      As of
      Aug 26, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      165.3K
      Value
      $890.7K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      54.3%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Cluster buy
      Net (90d)
      +$1.5M
      Buyers / Sellers
      3 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $75.1M
      Net income (FY)
      $-146.4M
      EPS diluted
      $-0.49
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 13, 2026
      This year
      18
      View
      Exempt Offerings
      Offering
      $74.5M
      Filed
      May 27, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View
      Investor Relations
      Latest news
      AbCellera Announces Pricing of Ov…
      Published
      Aug 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ABCL +1.9% +127.1% +241.0% +114.4% +257.9%
      SPY -0.4% +5.0% +12.4% +2.6% +12.3%
      vs SPY +2.3% +122.1% +228.5% +111.8% +245.6%
      Key facts CIK 1703057 CUSIP 00288U106 13F (30d) 124 filings 124 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)